98 results about "Oral glucose tolerance" patented technology

The invention relates to the technical field of microorganisms, and discloses bifidobacterium adolescentis and an application thereof. The collection number of the bifidobacterium adolescentis CCFM8630 is CGMCC No.14395. The bifidobacterium adolescentis CCFM8630 has the advantages that the level of neurotransmitter 5-hydroxytryptamine in peripheral blood of rats can be remarkably upgraded by the bifidobacterium adolescentis CCFM8630; the increased level of hormones such as testosterone in the peripheral blood of the rats due to high-glucose and high-fat diet and anomaly of abundance of Blautiaand Turicibacter in intestinal floras of the rats can be recovered; simulated gastrointestinal fluid can be tolerated, the bifidobacterium adolescentis can be quickly colonized in intestinal tracts,accordingly, rat livers with metabolic syndromes, pathological injury of duodenums and increase of the contents of triglyceride and total cholesterol in serum due to the high-glucose and high-fat dietand oral glucose tolerance can be remarkably improved, and the bifidobacterium adolescentis can be used for preventing, relieving or treating metabolic disorder such as the metabolic syndromes, irritable bowel syndromes and psychological illnesses such as anxiety and depression which are related to the metabolic syndromes.

The present invention encompasses a model-based method for determining insulin sensitivity and glucose absorption from oral glucose tolerance tests or mixed meals. The present invention has several advantages over current methods. The technique requires about four to six blood samples taken over about two to three hours following glucose ingestion and is therefore applicable to large-scale clinical trials. The analysis involves a reduced version of the classical minimal model, a method for describing glucose absorption using only two parameters, and an integral approach enabling the parameters to be obtained using simple algebra. The present method robustly identifies differences in insulin sensitivity in different patient types as well as improvements in insulin sensitivity arising from pharmaceutic therapy. In addition, insulin sensitivity measurements obtained with the present method are highly correlated with results from hyperinsulinemic clamps (r2>0.8). This method is therefore a practical and robust method for determining insulin sensitivity under physiologic conditions.

The invention discloses bifidobacterium bifidum CCFM1063 and application thereof. The bifidobacterium bifidum CCFM1063 can be rapidly planted in an intestinal tract, fasting blood-glucose and oral glucose tolerance caused by type II diabetes is significantly improved, and the area under the curve for glucose tolerance is reduced; total cholesterol in a serum increased and high-density lipoproteincholesterol reduced caused by the type II diabetes are significantly improved; the condition of insulin resistance caused by the significantly improved is significantly improved; the level of inflammation in type II diabetes liver tissue is significantly improved; pathological injuries of tissue such as pancreas and liver caused by the type II diabetes are significantly improved; the bifidobacterium bifidum CCFM1063 has higher adsorption capacity on perfluoro caprylic acid, and has the capacity of relieving toxicity of the perfluoro caprylic acid; and the constipation condition caused by the type II diabetes is significantly improved and the level of Allobaculum genus in the intestinal tract is improved, and functions of relieving anxiety and depression and colonitis are achieved.

The invention discloses a moringa leaf extract with blood sugar lowering activity and a preparation method thereof. The preparation method comprises the following steps: crushing and sieving, performing alkali treatment, performing protease enzymolysis, performing cellulase enzymolysis, performing high-pressure homogenization, performing high-temperature extraction, performing low-temperature high-speed centrifugation, performing ultrafiltration separation and concentration, performing protease enzymolysis, performing low-temperature high-speed centrifugation, performing secondary ultrafiltration separation and concentration, performing freeze drying and the like to obtain the moringa leaf extract with the blood sugar lowering activity. The extract has the polysaccharide content of 30% orabove; an animal experimental model of a type-2 diabetic rat verifies that the extract has good blood sugar lowering activity and can effectively reduce the fasting blood glucose of the type-2 diabetic rat and enhance the oral glucose tolerance dosage thereof; the acting effect of the extract is similar to that of metformin with the same dosage. An extracting technology is simple, the whole technological process can meet a food-grade requirement, and the moringa leaf extract can be applied to the field of medicines, health-care products, food and the like.

The invention relates to a glucose drink, which comprises 250 to 350g of aerated water, citric acid and glucose, wherein the weight of the glucose is 50g, 75g or 100g. The aerated water and the citric acid contained in the drink can improve the taste both. After the oral glucose tolerance test, the tester does not feel nausea or other discomforts, so that the test is carried out smoothly. When the weight of the glucose is 50g, 75g or 100g, the requirements on the oral glucose tolerance test are met. The invention also provides a method for preparing the glucose drink.

The invention discloses bifidobacterium pseudocatenulatum CCFM1046, a composition, a fermented food, applications, a microbial inoculum and a preparation method thereof. As the bifidobacterium pseudocatenulatum CCFM1046 can tolerate gastrointestinal environments in human bodies, the rising of hepatic triglyceride content of metabolic syndrome mice caused by high-fat diet can be significantly improved; the weight increasing of the metabolic syndrome mice can be alleviated; the abnormal fasting blood glucose and oral glucose tolerance of the metabolic syndrome mice can be significantly improvedas well; area under the curve of glucose tolerance can be reduced; serum insulin levels can be enhanced; the rising of low-density lipoprotein cholesterol in serum of the metabolic syndrome mice caused by the high-fat diet can be significantly improved; and the rising of Proteus genus in intestinal tracts caused by the high-fat diet can also be significantly improved. The bifidobacterium pseudocatenulatum CCFM1046 can be used for preparing the pharmaceutical composition and fermented food for alleviating metabolic syndromes and decreasing the occurrence of Parkinson, intestinal infection, urinary tract and kidney infection and other diseases, so that the bifidobacterium pseudocatenulatum CCFM1046 can have very wide application prospects.

The invention patent relates to the technical field of animal experiment model construction, in particular to a construction method for a mouse type 2 diabetes mellitus (T2DM) animal experiment model. The method includes the following steps: male Kunmin mice at the age of 7 to 31 days are selected; 50 to 75 mg / Kg (milligrams per kilogram) of streptozotocin is taken by the mice through intraperitoneal injection at a time; after the mice are continuously fed with high-fat high-glucose feed for 4 to 6 weeks upon free eating, the mice of which fasting blood-glucose is above 7.0 millimoles per liter, blood glucose in a 2-hour oral glucose tolerance test is above 11.1 millimoles per liter, cholesterol is above 5.7 millimoles per liter, triglyceride is above 1.7 millimoles per liter, and high-density lipoprotein is below 1.0 millimole per liter at the same time are defined as T2DM animal experiment models. The model can simulate the T2DM characteristics of humans, and adopts multiple testing indicators to accurately define T2DM; due to the light weights of the underage animals, the streptozotocin dosage is small, so that the experiment cost is reduced.

The invention belongs to the field of traditional Chinese medicine manufacturing, and relates to application of leonurine to preparation of a medicament for treating 2-type diabetes. Animal experiments prove that the fasting blood glucose of a 2-type diabetes mouse, i.e., a db / db mouse, can be lowered by the leonurine, and the tolerance of oral glucose is improved; and meanwhile, fasting plasma insulin is increased, the plasma triglyceride is reduced and the content of the plasma high-density lipoprotein is increased. Experiment results also show that the expression of liver glucose metabolic enzymes such as glucokinase, glucose-6-phosphatase and phosphoenolpyruvate carboxyl enzyme is adjusted by the leonurine in an Akt dependent mode; and the biological response of an inflammatory mediator, such as generation of TNF (Tumor Necrosis Factor)-alpha, degradation of IkB-alpha and subsequent phosphorylation of NF-kBp65, is suppressed. Through the leonurine, the inflammatory state of the 2-type diabetes can be corrected, and the symptoms of the 2-type diabetes can be improved; and the leonurine can be used as a treatment medicament to be applied to the treatment of the 2-type diabetes.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a drop in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

The present invention encompasses a model-based method for determining insulin sensitivity and glucose absorption from oral glucose tolerance tests or mixed meals. The present invention has several advantages over current methods. The technique requires about four to six blood samples taken over about two to three hours following glucose ingestion and is therefore applicable to large-scale clinical trials. The analysis involves a reduced version of the classical minimal model, a method for describing glucose absorption using only two parameters, and an integral approach enabling the parametersto be obtained using simple algebra. The present method robustly identifies differences in insulin sensitivity in different patient types as well as improvements in insulin sensitivity arising from pharmaceutic therapy. In addition, insulin sensitivity measurements obtained with the present method are highly correlated with results from hyperinsulinemic clamps (r<2>>0.8). This method is thereforea practical and robust method for determining insulin sensitivity under physiologic conditions.

Analysis of full-blood glucose, serum insulin, serum triglycerides and total serum cholesterol were performed. Glucose levels in blood samples from the oral glucose tolerance test were used for calculation of the incremental Area Under the Curve (AUC0-120 min-baseline). All data are expressed as percentage change of vehicle treated animals (cf. FIGS. 1 and 2).

The invention relates to the field of gene engineering, and discloses a construction and an expression for two engineering bacteria of two human glucagon-like peptide-1 analogues, and a preparation method for the objective peptides. The objective peptides are formed by inserting objective sequence after double digestions, adding His labels at the front ends of fusion proteins, obtaining objective peptides by cutting the fusion proteins with acid via gaining the fusion proteins, and after an isoelectric precipitation, obtaining the objective peptides again through an affinity chromatography of a Ni agarose gel after an isoelectric precipitation. Freeze-dried objective peptides are dissolved in a PBS buffer solution, oral glucose tolerance test and determination of serum insulin concentration are carried out on normal ICR mice. The two analogues are modified peptides of human glucagon-like peptide-1. Experiments demonstrate that both the two peptides have effects for reducing blood glucose and can be used for treating type 2 diabetes mellitus. Furthermore, the invention also provides the preparation method for the peptides.

The invention discloses pharmaceutical application of a phenoxy acid derivative and belongs to the field of biomedicine.The phenoxy acid derivative and berberine are chemically synthesized into salt, the problem that phenoxy acid derivative medicine is poor in water solubility and low in oral bioavailability, and consequently full play of the pharmaceutical effect of the medicine is limited is solved, and the problems that berberine hydrochloride is low in water solubility and lower in fat solubility, malabsorption by the gastrointestinal tract is caused, as a result, the oral bioavailability of berberine hydrochloride is low, and the systematic treatment effect of berberine hydrochloride is affected are solved.The derivative shows an excellent effect on regulating the blood glucose and blood fat of a rat with 2-type diabetes in an animal experiment.The derivative has the main effects of improving the oral glucose tolerance, promoting insulin secretion, improving insulin resistance, reducing the amount of triglyceride and the like.

The invention provides an automatic process processing method and an automatic executing module for a new OGTT (Oral Glucose Tolerance Test). The automatic process processing method comprises the following steps: A, respectively sending samples which are sampled at a plurality of time points when a patient is on an empty stomach and after the patient takes glucose to a testing laboratory of a hospital for testing in real time; B, after the sample in any time period is received by the testing laboratory of the hospital, originally managing the sample in a biochemical immune pipeline detection system of the testing laboratory of the hospital for feeding the sample, and performing the operations of automatically centrifuging, automatically uncovering, automatically testing, automatically storing the sample and the like; C, after the samples which are sampled at a plurality of different time periods are tested by the biochemical immune pipeline detection system of the testing laboratory of the hospital, automatically merging to form an OGTT result according a time sequence; D, transmitting the OGTT result to an LIS (Laboratory Information System) for checking and issuing. According to the automatic process processing method and the automatic executing module for the new OGTT, full-automatic operation is realized; the efficiency is high; the work intensity of a worker is greatly lightened; the testing result is accurate; the testing report period is shortened.

The present invention is directed to pyridin-2-one derivatives, pharmaceutical compositions containing them and their use as antagonists of the EP3 receptor, for the treatment of for example, impaired oral glucose tolerance, elevated fasting glucose, Type II Diabetes Mellitus, Syndrome X (also known as Metabolic Syndrome) and related disorders and complications thereof.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

The invention provides a synthetic method of a 9-substituted dual functional group berberine derivative, belonging to the field of chemical synthesis. Discovered by pharmacological experiments, the derivative has multiple values of medicinal activity, especially has easy absorbability which other medicines do not have, and concretely the derivative shows excellent effects on regulating the blood sugar and blood fat of rats with diabetes type 2 in animal experiments. The main effects of the 9-substituted dual functional group berberine derivative are embodied in improving orally administered glucose tolerance, promoting insulin secretion, improving insulin resistance, lowering the level of triglyceride and the like.

The present invention relates to a health care product, in particular to a post meal glucose-stabilized convenient nutrition conjee and the preparation method thereof, which can stabilize the blood glucose after meal. The present invention provides a convenient nutrition conjee which can stabilized the blood glucose after meal, wherein the brown rice and buckwheat rice in the prescription keep the nutritious elements and the fibers to the largest extent, while the rutin and chlorophyll contained in the buckwheat rice is what the other corn corps lack, and the minerals and the vitamins of the buckwheat rice are also higher than the level of the other crops, wherein based on the medical research, the flavone of the buckwheat rice has multiple functions of anti-oxidation, decrease blood glucose, and decrease blood lipid. The post meal glucose-stabilized convenient nutrition conjee provided by the present invention can balance the nutrition, act against oxidization, meliorate the insulin resistance, decrease the dosage of the glucose-lowering drugs, improve the insulin utilization rate of the patient, effectively improve the level of oral glucose tolerance test (OGTT) and the level of glycated haemoglobin (HbALC), improve the quality of life of the patient, prevent from the complications, and be in favor of the intake by the diabetes patient.

The invention discloses lactobacillus casei for prevention and auxiliary treatment of type II diabetes and application of the lactobacillus casei. The lactobacillus casei LCZ has a remarkable functionof preventing type II diabetes and the process of the type II diabetes can be well prevented after the lactobacillus casei intervenes for two weeks; the weight increase of a high-fat diet mice can beintervened and delayed, and the oral glucose tolerance increase induced by high-fat diet is prevented; expression of intestinal tract iron-related protein (transferrin and iron transport carrier protein) can be improved, chronic inflammation caused by endotoxin entering tissue is reduced, and then the effect of lowering the hyperglycemia level is achieved. Due to the remarkable functional characteristics of the lactobacillus casei, the lactobacillus casei has wide application value in various forms of probiotic foods, such as probiotic tabletting candies and probiotic solid beverages.

The invention belongs to the technical field of food processing, and particularly relates to a preparation method and application of radix puerariae resistant starch. The radix puerariae resistant starch is obtained by sequentially pre-gelatinizing, autoclaving and breaking down, with debranching enzyme, radix puerariae starch milk. According to the preparation method, after the autoclaved adix puerariae resistant starch is obtained, the debranching enzyme only needs to be added once, so that the step of repeated enzymolysis treatment is avoided, and the method is simple and efficient; and the prepared resistant starch can enable the blood sugar level of diabetic mice to be in a trend of decreasing to different degrees along with time change, the insulin function is gradually recovered, the oral glucose tolerance is effectively relieved, and the resistant starch has a extremely good effect of reducing blood sugar and blood fat.

The invention provides a compound shown in the formula I or pharmaceutically acceptable salts, hydrates or solvates thereof, and also provides new application of the compound or the pharmaceutically acceptable salts, hydrates or solvents thereof. A deuterated compound can be used for remarkably improving the conditions of the weight, fasting blood-glucose, transaminase and fasting serum insulin of an obese patient, increasing the insulin sensitivity can be improve, and enhancing the serum lipid parameter and oral glucose tolerance; the compound has the advantages that internal absorption effect is excellent;, the bioavailability is high, which is favorable for the taking of drug effect; the half-life period is prolonged, so that the administration frequency can be reduced and toxic and side effects can be reduced; therefore a new safe and reliable choice is provided to clinical administration. The formula I can be found in the specification.

The invention relates to the technical field of probiotics, in particular to a composition of lactobacillus paracasei LC-37 and application of the composition in reducing blood sugar. According to the invention, the lactobacillus paracasei LC-37 has new functions of promoting the secretion of the glucagon-like peptide 1, reducing blood sugar and relieving the symptoms of diabetes mellitus; the lactobacillus paracasei LC-37 is further compounded with the dietary fibers, the GLP-1 secretion promoting effect of the lactobacillus paracasei LC-37 is remarkably improved, and the composition of the lactobacillus paracasei LC-37 and the dietary fibers can remarkably reduce the blood glucose of diabetic animals, relieve oral glucose tolerance damage, reduce the insulin resistance index and regulate blood fat. The traditional Chinese medicine composition can improve intestinal mucosal barrier and pancreatic tissue damage, has a certain relieving effect on type II diabetes, and is safe, reliable and free of side effects.

The invention discloses a xanthine derivative and its pharmaceutically acceptable salt. In vitro DPP-IV activity inhibition tests, influence tests of normal mouse's glucose tolerance, and influence tests of spontaneous diabetic mouse's blood glucose confirm that the compound and its pharmaceutically acceptable salt show significant DPP-IV inhibitory activity, and can be used in preparation of drugs for treating dipeptidyl peptidase IV associated diseases.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and / or nitrate.

The invention provides a synthetic method of 9-position substituted di-functional-group berberine derivatives, and belongs to the field of drug synthesis. A pharmacological experiment proves that the derivatives have the drug activities of various values and have the absorbable performance which the other drugs do not have, and particularly the derivatives have the excellent effects of adjusting blood glucose and blood fat of rats suffering from type-II diabetes. The derivatives have the main effects that the oral glucose tolerance can be improved, insulin secretion can be promoted, insulin resistance can be improved, and the amount of triglyceride can be lowered.

The invention relates to a microbial composition for preventing or treating type II diabetes mellitus as well as a preparation method and application thereof. The microbial composition for preventing or treating type II diabetes mellitus comprises a bifidobacterium longum BL21 strain and a lactobacillus rhamnosus LRa05 strain. The microbial composition can obviously reduce the body weight of a patient with type II diabetes mellitus; the levels of ALT, AST and the like in the serum of the type II diabetes mellitus patient are obviously reduced; the levels of serum inflammatory factors such as TNF-alpha and IL-1beta are reduced; the increased fasting blood glucose level and the area under the curve in the oral glucose tolerance test are significantly reduced; the DX-4000-FITC level of the plasma at the time of 2.5 hours is obviously reduced and the plasma LPS level is obviously reduced. Therefore, the microbial composition has a great application prospect in preparation of medicines, foods or health-care products for preventing, treating and relieving type II diabetes mellitus.

The invention discloses preparation and medical application of a glinides berberine coupling compound, and belongs to the field of biological medicine. A glinides derivative and berberine are chemically synthesized into salt, and the problems that floxacin derivative medicine is poor in water solubility and low in oral administration bioavailability, and consequently full play of the medicine effect of floxacin derivative medicine is limited are solved. The problems that berberine hydrochloride is small in water solubility, smaller in lipid solubility and poor in gastrointestinal tract absorption, consequently the oral administration bioavailability of berberine hydrochloride is low, and the whole body treatment effect of berberine hydrochloride is influenced are solved. The derivatives show an excellent effect on regulating the blood glucose of 2-type diabetes rats in animal tests. The glinides berberine coupling compound mainly has the effects of being capable of improving oral glucose tolerance, promoting insulin secretion, improving insulin resistance and the like.